JWJian-Jun Wu

Jian-Jun Wu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jian-Jun Wu has a total of 157 co-authors. Here are the top co-authors by number of shared publications:

  • Jian Wang

    Department of Neurology and National Research Center for Aging and Medicine & National Center for Neurological Disorders, State Key Laboratory of Medical Neurobiology, Huashan Hospital, Fudan University, Shanghai, 200040, China

    21 shared publications
  • Yi-Min Sun

    Department of Neurology and National Research Center for Aging and Medicine and National Center for Neurological Disorders, State Key Laboratory of Brain Function and Disorders, Huashan Hospital, Fudan University

    11 shared publications
  • Feng-Tao Liu

    Department of Neurology and National Research Center for Aging and Medicine & National Center for Neurological Disorders, State Key Laboratory of Brain Function and Disorders, Huashan Hospital, Fudan University, Shanghai, China

    8 shared publications
  • Bo Shen

    Department of Neurology, National Research Center for Aging and Medicine, National Center for Neurological Disorders, State Key Laboratory of Medical Neurobiology, Huashan Hospital, Fudan University, Shanghai, China

    7 shared publications
  • Feng-Tao Liu

    Department of Neurology, National Research Center for Aging and Medicine, National Center for Neurological Disorders, State Key Laboratory of Medical Neurobiology, Huashan Hospital, Fudan University, Shanghai, China

    7 shared publications
  • Jue Zhao

    Department of Neurology, National Research Center for Aging and Medicine, National Center for Neurological Disorders, State Key Laboratory of Medical Neurobiology, Huashan Hospital, Fudan University, Shanghai, China

    7 shared publications

Latest Publications

  • Open Access

    Distinct contributions of two subpopulations of subthalamic neurons to levodopa-induced dyskinesia

    by Bo Shen, Linlin Han, Yan Xiao, Cong Shen, Ziwei Le, Bin Wu, Lu Su, Wenbo Yu, Yimin Sun, Fengtao Liu, et al.

    The subthalamic nucleus (STN) is a prominent target for deep-brain stimulation (DBS) in the treatment of levodopa-induced dyskinesia (LID), a common motor complication of Parkinson’s disease. However, the precise impact of STN-DBS on LID remains unclear. Here, we investigated the functional roles of two distinct neuronal populations within the STN in regulating LID. In a mouse model of LID, STN neurons projecting to the entopeduncular nucleus (EP) exhibited a U-shaped activation pattern, whereas those projecting to the tegmental reticular nucleus (RtTg) displayed a predominantly inhibitory response. Activation of EP-projecting STN neurons alleviated dyskinesia but worsened hypokinesia in the parkinsonian state. Activation of RtTg-projecting STN neurons alone did not induce hyperkinetic characteristics, except when combined with levodopa. These findings reveal two anatomically and functionally distinct populations of STN neurons involved in LID regulation, offering insights into the circuitry underlying STN-DBS.


  • Open Access

    Editorial: AI-powered advances in diagnosis and management of movement disorders

    by Yi-Min Sun, Gao-Wei Xu, Guang-Ming Zhang, Jian-Jun Wu

    Movement disorders are a group of neurological conditions caused by dysfunction of the nervous system that affect the speed, quality, and ease of movement. They can be broadly classified into hyperkinetic (excessive movement) and hypokinetic (slow movement) types. The phenomenology of movement disorders is critical since it acts as a clue to the etiological diagnosis and symptomatic treatments. Traditionally, the assessments of the phenotype are carried out using the scales by the clinical raters. In addition to inter-rater inconsistency, which is always an issue, scale evaluations are time-consuming and limited by clinical settings, all of which affect their objective assessment of symptoms and treatment efficacy, particularly in real-world scenarios requiring continuous monitoring of the disease. Moreover, lots of useful information might be missed in the data collecting by digital materials of video and audio recordings, neuroimaging, electrophysiological signals, wearable sensors if they are analyzed by traditional methods.Artificial intelligence (AI) based methods, especially the novel data driven models using machine learning and deep learning, showed potentials for interpreting complex data into quantifiable metrics, which have revolutionized medical data analysis and image processing, assisting in deep phenotyping (1), diagnosis (2, 3), identifying digital biomarkers(4), remote screening (5) and monitoring in movement disorders (6). Chen et al. proposed a method to classify PD from healthy controls, using voice recordings of the subjects. In their study, three pre-trained deep learning models (convolutional neural networks) were used to extract features from the spectrograms converted from the speech segments, followed by feature fusion.The fusion of 2 models achieved the highest accuracy of 95.56% and an AUC of 0.99, better than the best single model (92.73% accuracy).These methods provide a low-cost, non-invasive and a convenient tool for PD diagnosis. They also emphasized the importance of multimodal framework and multi-model integration in the proposed mode, since the different data types and different algorithms attained better model performance.Non-motor symptoms were important but seemed less enrolled as phenotype in the AI analysis. Here, Serbee et al. investigated the association between hypomimia and sialorrhea in PD by AI base video analysis of a 10second videos of happy facial expressions and found the moderate correlations between sialorrhea rating scales and features derived from facial regions. The videos were analyzed using AI algorithms to extract key facial landmarks which were then processed into 20 quantitative features representing mouth, eyes, and combined facial regions. Principal Component Analysis, Canonical Correlation Analysis, and bootstrapping were applied. Their study indicated the video-based assessment tools may also be extended to screen for non-motor symptoms, which broadened the scope of digital phenotyping in PD.AI based approach quantifying motor symptoms first characterized the kinematic effects of levodopa on PD related motor features and found 3 kinematic domains of speed, consistency, timing/scale improved by levodopa, reported by Lange and colleagues in 2025, describing the effects of treatments unable to be detected by conventional scales (7). The unqualified or inconsistent data, patients' privacy protection, poor model generalization, lack of real-world validation or external validation, blackbox effect, might be the challenges and concerns of AI in movement disorders and should be improved in the future (6). Finally, it is important to point out that AI serves as an auxiliary tool for diagnosis and management in movement disorders, but it could not replace the role of a physician currently (8).

  • Open Access

    AI-based retrospective analysis: differential improvement profiles of medication and deep brain stimulation in Parkinson's disease

    by Lu Su, Aiwen Li, Zhanxu Li, Yilin Liu, Geng Cheng, Bo Shen, Jian Wang, Jianjun Wu

    Background: Bradykinesia in Parkinson's disease (PD) involves reduced movement speed, amplitude, and rhythmicity. While the MDS-UPDRS Part III is the standard clinical tool for motor assessment, it has limited sensitivity to specific kinematic features. Levodopa and subthalamic nucleus deep brain stimulation (STN-DBS) are common treatments for PD, yet their differential effects across motor domains are not fully characterized. This study applies AI-based video analysis to evaluate the effects of levodopa and STN-DBS on limb bradykinesia. Methods: This retrospective study assessed fifty-three patients with Parkinson's disease undergoing STN-DBS. Motor performance was video-recorded during Levodopa-off and Levodopa-on states (levodopa challenge test performed prior to surgery), as well as after DBS activation (OFF MED /OFF STIM , OFF MED /ON STIM , ON MED /ON STIM ). Both clinical assessments and subsequent video-based analyses focused on the MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), Part III, specifically evaluating items 3.4 Finger Tapping, 3.5 Fist-clenching test, 3.7 Toe Tapping, and 3.8 Leg Agility. Motor function was first evaluated using conventional UPDRS-III item scores rated by two experienced specialists, with the primary clinical comparison defined between the levodopa-on and OFF MED /ON STIM states, to explore the differential therapeutic emphases of medication and DBS. Subsequently, AI-based video analysis was applied to quantify kinematic parameters, including amplitude, frequency, and coefficients of variation, using AI algorithms (NERVTEX Co. Ltd.). Comparisons were made for levodopa effects (Levodopa-off vs. Levodopa-on), DBS effects (OFF MED /OFF STIM vs. OFF MED /ON STIM ), and therapy-specific differences (Levodopa-on vs. OFF MED /ON STIM ). Results: Conventional UPDRS-III item scores suggested that levodopa was more effective than DBS in improving upper-limb tasks (items 3.4 Finger Tapping and 3.5 Fist-clenching test), while lower-limb tasks (items 3.7 Toe Tapping and 3.8 Leg Agility) showed no significant changes. In contrast, AI-based kinematic analysis revealed more differentiated treatment effects. Levodopa was associated with improvements in movement speed, amplitude, and stability in the upper limbs, as well as a significant impact on lower-limb amplitude, both in toe tapping (item 3.7) and leg agility (item 3.8). DBS, by comparison, enhanced upper-limb motor output but had limited effects on the lower limbs, with improvements in speed and amplitude observed only in the toe tapping (item 3.7) task. Additionally, levodopa demonstrated superior improvements in lower-limb amplitude, both in toe tapping (item 3.7) and leg agility (item 3.8), compared to DBS. Conclusion: This study demonstrates that AI-based kinematic analysis enables a nuanced and individualized characterization of motor responses to medication and STN-DBS in Parkinson's disease, complementing conventional clinical scoring. Although both therapies improve bradykinesia, they appear to preferentially modulate distinct motor domains across individuals, underscoring their complementary roles in treatment. These findings highlight the potential of AI-based motor assessment to support personalized symptom profiling and more individualized therapeutic decision-making in Parkinson's disease.

  • Evaluating the Clinical Utility of a Machine Learning Model for Diagnosing Parkinson’s Disease Using Acoustic Parameters

    by Zhiheng Xu, Liwen Li, Xining Liu, Xiaoniu Liang, Mindi Yang, Yi Chen, Xixi Han, Jian Wang, Yilin Tang, Menghan Zhang, et al.


  • Open Access

    The homozygous LRRK2.p.N1437D point mutation mouse is a novel model of parkinsonism

    by Lin-Hua Gan, Yi-Min Sun, Xin-Yue Zhou, Zhi-Yuan Qi, Feng-Tao Liu, Yi-Lin Tang, Wen-Bo Yu, Bao-Guo Xiao, Jian Wang, Jian-Jun Wu

    The leucine-rich repeat kinase 2 (LRRK2) gene is one of the most common genetic causes of autosomal dominant Parkinson’s disease (PD) and a common genetic risk factor for sporadic PD. However, aged mice with common LRRK2 point mutations fail to exhibit age-related PD-associated behavioral and pathological impairments. We generated a novel mouse model harboring the LRRK2.p.N1437D point mutation (c.4309 A > G; NM_98578). Here, the homozygous N1437D mutation, but not the heterozygous mutation, led to an increase in the autophosphorylation, substrate phosphorylation, and GTP-binding capacity of LRRK2. Heterozygous N1437D mice also showed unaffected behavior and pathology while the homozygous mice exhibited PD-associated behavioral change at 25–26 months, dopamine system damage, lipofuscin accumulation, and lipid peroxidation in substantia nigra dopaminergic neurons at 26–27 months. The new N1437D point mutation mouse does not require LRRK2 overexpression and may better mimic the pathological characteristics of LRRK2 mutation in the ROC-COR region.


  • Open Access

    Plasma GFAP and NfL associate with cerebral glucose metabolism in putative brain-first and body-first Parkinson’s disease subtypes

    by Shiyu Li, Fangyang Jiao, Xiuyuan Li, Zhiheng Xu, Tianyu Hu, Xiaoniu Liang, Jianjun Wu, Jian Wang, Chuantao Zuo, Yilin Tang

    The recently proposed body-first and brain-first subtypes are classified based on the initial localization of α-synuclein inclusions. This study investigated plasma biomarkers and cerebral glucose metabolism characteristics in putative brain-first and body-first subtypes in PD subjects. PD patients without possible RBD (PDpRBD–) (n = 58) and with possible RBD symptoms discovered before motor symptoms (PDpRBD+) (n = 43) were recruited. Single-molecule array (SimoA) was used for measuring plasma biomarkers, including glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), Tau and phosphorylated-tau 181 (pTau-181). All participants underwent 18F-fluorodeoxyglucose (FDG) PET scans. Compared to PDpRBD– patients, PDpRBD+ patients exhibited significantly increased plasma GFAP levels and reduced 18F-FDG uptake in cortical regions. Notably, plasma GFAP and NfL levels correlated with cerebral glucose metabolism in PDpRBD– patients. Our study identified the association between plasma GFAP and NfL levels and cerebral glucose metabolism in PDpRBD– patients. Further large-scale longitudinal studies are required.


  • Open Access

    Impact of deep brain stimulation on cognitive impairment in Parkinson’s disease: A retrospective longitudinal study

    by You Ni, Yan Xiao, Bo Shen, Yi-Min Sun, Jue Zhao, Bin Wu, Yi-Lin Tang, Feng-Tao Liu, Jian Wang, Jian-Jun Wu


  • Assessing Plasma APLP1 for the Progression of Parkinson's Disease: Insights from HSPD and PPMI Cohorts

    by You Ni, Ya‐Nan Yin, Wen‐Bo Yu, Yi‐Qi Liu, Jue Zhao, Yu‐Chen Yan, Wan‐Bing Zhao, Yi‐Lin Tang, Yi‐Min Sun, Feng‐Tao Liu, et al.

    Background: Amyloid precursor‐like protein 1 (APLP1) is involved in pathological α‐synuclein transmission, but its role in Parkinson's disease (PD) progression has not been explored.Objective: This study investigates APLP1 as a potential predictor for motor and cognitive deterioration in PD.Methods: Plasma APLP1 levels were measured in PD patients from the Huashan Hospital for Parkinson's Disease (HSPD) and Parkinson's Disease Progression Markers Initiative (PPMI) cohorts. A total of 916 participants were recruited in the HSPD cohort, and 171 participants were in the PPMI cohort. Longitudinal analysis examined the association between baseline APLP1 levels and PD progression.Results: A significant increase in APLP1 levels was observed in PD patients compared to healthy controls. Longitudinal analysis showed that patients with elevated baseline APLP1 levels experienced faster motor deterioration in HSPD cohort (HR = 3.627, P < 0.0001).Conclusions: The data indicate that APLP1 is associated with the progression of PD, potentially offering a measurable indicator of disease progression. © 2025 International Parkinson and Movement Disorder Society.


  • 18F‐Florzolotau PET Imaging Unveils Tau Pathology in Dementia with Lewy Bodies

    by Gan Tang, Jia‐Ying Lu, Xin‐Yi Li, Rui‐Xin Yao, Yu‐Jie Yang, Fang‐Yang Jiao, Ming‐Jia Chen, Xiao‐Niu Liang, Zi‐Zhao Ju, Jing‐Jie Ge, et al.

    Background: Dementia with Lewy bodies (DLB) commonly exhibits a complex neuropathology, sharing characteristics with Alzheimer's disease (AD), including tau aggregates. However, studies using the 18F‐AV‐1451 tau tracer have shown inconsistent findings regarding both the extent and topographical distribution of tau pathology in DLB.Objectives: Our aim was to elucidate the topographical patterns of tau deposition in DLB and to investigate the in vivo pathological distinction between DLB and AD in virtue of the 18F‐Florzolotau positron emission tomography (PET) imaging.Methods: This cross‐sectional study enrolled patients with DLB (n = 24), AD (n = 43), and cognitively healthy controls (n = 18). Clinical assessments and 18F‐Florzolotau PET imaging were performed. 18F‐Florzolotau binding was quantitatively assessed on PET images using standardized uptake value ratios and voxel‐wise analysis.Results: 18F‐Florzolotau PET imaging revealed widespread tau deposition across various cortical regions in DLB, uncovering heterogeneous topographical patterns. Among patients, 54.17% showed patterns similar to AD, whereas 16.67% exhibited distinct patterns. Compared to AD, DLB exhibited a unique in vivo neuropathological profile, characterized by a lower tau protein burden, heterogeneous topographical distributions, and a specific role of the medial temporal lobe in tau pathology.Conclusions: 18F‐Florzolotau PET imaging elucidated tau pathology patterns in DLB, providing valuable insights for future in vivo pathological differentiation and potential disease‐modifying therapies. © 2024 International Parkinson and Movement Disorder Society.


  • Bilateral Deep Brain Stimulation of Posterior Subthalamic Area in Patient with Spinocerebellar Ataxia Type 12

    by Yi‐Min Sun, Li‐Qin Lang, Xin‐Yue Zhou, Bo Shen, Jie Hu, Jian‐Jun Wu